IP Library › Granted Patent US 12,569,463
Granted Patent B2
US 12,569,463 · App. 17/934,526 · Granted Mar 10, 2026

Method for treating diabetes

Inventors: Charles A. Dinarello (Boulder, CO); Carlo Marchetti (Denver, CO); Marc Y. Donath (Rüschlikon, CH)
Assignee: OLATEC THERAPEUTICS, INC.
A61K31/275A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,569,463
App. No.
17/934,526
Filed
Sep 22, 2022
Granted
Mar 10, 2026
Kind
B2
Examiner
WARD, PAUL V
Art Unit
1622
USPC
514/402
Abstract

The present invention is directed to a method for treating diabetes. The method comprises administering to a subject in need thereof dapansutrile, or a pharmaceutically acceptable solvate thereof, in an effective amount. Oral administration is a preferred route of administration.

Claims (9)

1 . A method for treating diabetes, comprising the step of:

administering to a subject suffering from diabetes an effective amount of dapansutrile, or a pharmaceutically acceptable solvate thereof.

2 . The method according to claim 1 , wherein said method lowers hemoglobin A1C (HbA1c) level in the blood of the subject.

3 . The method according to claim 1 , wherein said method lowers the blood glucose level in the subject.

4 . The method according to claim 1 , wherein said method further prevents disease progression by treating microvascular inflammation in the subject.

5 . The method according to claim 1 , wherein the subject has heart failure.

6 . The method according to claim 1 , wherein dapansutrile is administered by systemic administration.

7 . The method according to claim 1 , wherein dapansutrile is administered by oral administration.

8 . The method according to claim 7 , where dapansutrile is administered 500-4000 mg/day.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2025
From: DINARELLO, CHARLES A.; MARCHETTI, CARLO; DONATH, MARC Y.
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 072689/0880 →
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
Continuity (3)
Continuation PCTUS2021023497 · Mar 22, 2021
Provisional Application 62994486 · Mar 25, 2020
Related Publication 20230028615A1 · Jan 26, 2023
References Cited (17)
US 20190307718A1 · Marchetti · 2019 [cited by examiner]
WO 2018204764A1 · 2018 [cited by applicant]
WO 2019023145A1 · 2019 [cited by applicant]
Huang et al., EMBO Molecular Med. (2018) (10), No. 4. [cited by examiner]
Hua et al., Journal of Experimental Med. (2017)vol. 214, No. 11 pp. 3219-3238. [cited by examiner]
Hua Jiang, et al., “Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders”, Journal of Experimental Medicine, vol. 214, No. 11, Oct. 11, 2017, pp. 3219-3238. [cited by applicant]
Huang Yi, et al., “3 to treat inflammasome-driven diseases”, Embo Molecular Medicine, vol. 10, No. 4, Mar. 12, 2018, https:onlinelibrary.wiley.com/doi/full-XML/10.15252/emmm.201708689. [cited by applicant]
Hongbin He, et al., “Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity”, Nature Communications, vol. 9, No. 1, Dec. 1, 2018, https://www.nature.com/articles/s41467-018-04947-6.pdf. [cited by applicant]
Sujuan Ding, et al., “Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes”, Biomolecules, vol. 9, No. 12, Dec. 9, 2019, p. 850. [cited by applicant]
Webmd, “Insulin Resistance”, Jul. 1, 2019, https://www.webmd.com/diabetes/insulin-resistance-syndrome. [cited by applicant]
United States Patent & Trademark Office (USPTO), International Search Report, PCT/US2021/023497, Jun. 8, 2021. [cited by applicant]
European Patent Office, Extended European Search Report, EPO Application No. 21774979.5, Mar. 27, 2024. [cited by applicant]
Jansen, TL et al., “P160 The first phase 2A proof-of-concept study of selective NLRP3 inflammasome inhibitor, dapansutrile (OLT1177), in acute gout”, Annals of the Rheumatic Diseases, Mar. 2019, A70-A71, vol. 78, Supple… [cited by applicant]
Zahid, Ayesha et al., Pharmacological Inhibitors of the NLRP3 Inflammasome, Frontiers in Immunology, Oct. 25, 2019, pp. 1-10, vol. 10, Article 2538. [cited by applicant]
Lee, Hye-Mi et al., Upregulated NLRP3 Inflammasome Activation in Patients with Type 2 Diabetes, Diabetes A Journal of the American Diabetes Association, Jan. 1, 2013, pp. 194-204, vol. 62, Issue 1, American Diabetes Ass… [cited by applicant]
Schroder, Kate et al., The NLRP3 Inflammasome: A Sensor for Metabolic Danger?, Science, Jan. 15, 2010, pp. 296-300, vol. 327, No. 5963, American Association forthe Advancement of Science. [cited by applicant]
Sharma, Arpeeta et al., Oxidative Stress and NLRP3-Inflammasome Activitiy as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications, Frontiers in Physiology, Feb. 20, 2018, vol. 9, Articl… [cited by applicant]